Amendments to the claims

Please amend claims 52, 56, 59, 63, 67, and 69.

Please cancel claims 53-55 and 64-65

Please add new claims 71-77.

1-51. **(Canceled)**

52. **(Currently Amended)** A composition comprising active lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins and inactive LT-β-R-Ig fusion proteins, wherein no more than 10% ~~30%~~ of the LT-β-R-Ig fusion proteins are inactive.

53-55. **(Canceled)**

56. **(Currently Amended)** The composition of claim 52 ~~any one of claims 52-54~~, wherein the active LT-β-R-Ig fusion proteins are recognized by a functional specific antibody.

57. **(Currently Amended)** The composition of claim 52 ~~any one of claims 52-54~~, wherein the LT-β-R-Ig fusion protein comprises ~~an~~ a human Fc domain.

58. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 57, and a pharmaceutically acceptable carrier.

59. **(Currently Amended)** The composition of claim 52 ~~any one of claims 52-54~~, wherein the Fc domain is of an IgG1 isotype.

60 ~~62.~~ **(Previously Presented)** A pharmaceutical composition comprising the composition of claim 59, and a pharmaceutically acceptable carrier.

61 ~~63.~~ **(Currently Amended)** A composition comprising active and inactive lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins, wherein no more than 10% ~~30%~~ LT-β-R-Ig fusion proteins are inactive, and wherein the active LT-β-R-Ig fusion proteins are obtained by culturing a mammalian host cell transformed with DNA encoding

the LT-β-R-Ig fusion protein in a culture system having a temperature of about 27° C to less than about 30 ~~35~~° C

62-64

~~64-66~~. **(Canceled)**

65 61

~~67~~. **(Currently Amended)** The composition of claim ~~63~~ ~~any one of claims 63-66~~, wherein the LT-β-R-Ig fusion protein comprises ~~an~~ a human Fc domain.

66

~~68~~. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim ~~67~~ 65, and a pharmaceutically acceptable carrier.

67 65

~~69~~. **(Previously Presented)** The composition of claim ~~67~~ ~~any one of claims 63-66~~, wherein the Fc domain is of an IgG1 isotype.

68

~~70~~. **(Previously Presented)** A pharmaceutical composition comprising the composition of claim ~~69~~ 67, and a pharmaceutically acceptable carrier.

69

~~71~~. **(New)** The composition of claim 52, wherein the active LT-β-R-Ig fusion proteins are glycosylated.

70

~~72~~. **(New)** A composition comprising active lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins and inactive LT-β-R-Ig fusion proteins, wherein no more than 6% of the LT-β-R-Ig fusion proteins are inactive.

71 70

~~73~~. **(New)** The composition of claim ~~72~~, wherein the LT-β-R-Ig fusion protein comprises a human Fc domain.

72 70

~~74~~. **(New)** The composition of claim ~~72~~, wherein the active lymphotoxin-β-receptor immunoglobulin (LT-β-R-Ig) fusion proteins are glycosylated.

73

~~75~~. **(New)** A pharmaceutical composition comprising the composition of claim ~~72~~ 70, and a pharmaceutically acceptable carrier.

74 71

~~76~~. **(New)** The composition of claim ~~73~~, wherein the Fc domain is of an IgG1 isotype.

75 74
~~77.~~ **(New)** A pharmaceutical composition comprising the composition of claim ~~76~~, and a pharmaceutically acceptable carrier.